Species |
Human |
Protein Construction |
BMP-7 (Ser293-His431) Accession # P18075 |
|
Purity |
> 95% as analyzed by SDS-PAGE > 95% as analyzed by HPLC |
Endotoxin Level |
< 0.2 EU/μg of protein by LAL method |
Expression System |
E. coli |
Theoretical Molecular Weight |
15.7 kDa |
Application |
1. Molecular standard (Western, ELISA) in studying secreted BMP-7; 2. Preparing antibodies for BMP-7 monomer; 3. Molecule standard in detecting secreted BMP-7 in reduced SDS-PAGE. |
Formulation |
Lyophilized from a 0.2 µm filtered solution in 30% acetonitrile, 0.1% TFA. |
Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in 10 mM HAc to a concentration of 0.1-1.0 mg/mL. |
Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles. |
Target Background |
Human BMP-7 is one of at least 15 structurally and functionally related BMPs, which are members of the transforming growth factor β (TGF-β) superfamily. BMPs were originally identified as protein regulators of cartilage and bone formation. However, they havesince been shown to be involved in embryogenesis and morphogenesis of various tissues and organs. BMPs have also been shown to regulate the growth, differentiation, chemotaxis and apoptosis of various cell types, including mesenchymal cells, epithelial cells, hematopoietic cells and neuronal cells. BMP-7 is synthesized as large precursor molecules which are cleaved by proteolytic enzymes. The active form can consist of a dimer of two identical proteins or a heterodimer of two related bone morphogenetic proteins. |
Synonyms |
Bone morphogenetic protein 7; Osteogenic protein 1; OP-1; INN: Eptotermin alfa; BMP7 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.